Borders Without Barriers: Building Global Cannabis Clinical Trials That Scale

Panel DiscussionPharmaceutical & Clinical Research

Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical trial collaboration has become the fastest route to credible data, regulatory approval, and commercial scale. Yet most operators still struggle with mismatched standards, fragmented data-sharing rules, and approval timelines that differ by jurisdiction.

This session maps the current global trial landscape and the real obstacles to cross-border partnership: harmonizing pharmaceutical standards, navigating conflicting regulations, and protecting data integrity across regions. You'll see how shared evidence accelerates product development and unlocks new cannabis industry opportunities in markets that demand clinical proof.

Drawing on current cannabis market trends, our experts connect research strategy to commercial reality, showing how global collaboration shortens the path from study to shelf. Built for pharmaceutical executives, researchers, and senior operators, this is a strategy-focused discussion with practical, real-world frameworks.

More Information

Tags:Pharmaceutical & Clinical Research Insights

Allow Registration:No

Capacity Unlimited:No

Related Sessions

Wed Dec 02•2:00 PM – 2:40 PM•Breakout Session Room 4 - N115

Google Calendar Apple Calendar Outlook Download .ICS file

The Cannabinoid Drug Pipeline: From Clinical Trials to Market

Cannabinoid-based pharmaceuticals are moving from promise to practice,…Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the indus…Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session gives pharmaceutical executives, investors, and researchers a perspective of where clinical development stands today and where the real cannabis industry opportunities sit next. Y…Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session gives pharmaceutical executives, investors, and researchers a perspective of where clinical development stands today and where the real cannabis industry opportunities sit next. You'll learn how to navigate the FDA regulatory pathway, structure clinical trials that withstand scrutiny, and align early-stage research with cannabis business compliance expectations. We'll break down the drug development process stage by stage, then turn to commercialization: pricing, payer access, manufacturing scale, and partnership models that bring a cannabinoid drug to patients. By the end, you'll leave with a strategic framework for evaluating pipelines, de-risking development, and timing market entry. Show MoreClick the title to see all detailsShow More

Panel DiscussionSession TypePharmaceutical & Clinical ResearchSession Track

More InformationExpand it to see more information related session.

Tags:Pharmaceutical & Clinical Research Insights

Allow Registration:No

Capacity Unlimited:No

Wed Dec 02•2:50 PM – 3:30 PM•Breakout Session Room 4 - N115

Google Calendar Apple Calendar Outlook Download .ICS file

Bridging the Gap: Medical Cannabis Science and Physician Education

Patients are asking about medical cannabis faster than most providers …Patients are asking about medical cannabis faster than most providers can answer. Many physicians never received formal training on cannabinoid science, dosing, drug interactions, or the patchwork of state regulations that shape what they can legally…Patients are asking about medical cannabis faster than most providers can answer. Many physicians never received formal training on cannabinoid science, dosing, drug interactions, or the patchwork of state regulations that shape what they can legally recommend. That knowledge gap leaves clinicians uncertain, patients underserved, and businesses exposed to compliance risk. This session tackles the problem on two fronts. First, we strengthen pro…Patients are asking about medical cannabis faster than most providers can answer. Many physicians never received formal training on cannabinoid science, dosing, drug interactions, or the patchwork of state regulations that shape what they can legally recommend. That knowledge gap leaves clinicians uncertain, patients underserved, and businesses exposed to compliance risk. This session tackles the problem on two fronts. First, we strengthen provider understanding of medical cannabis science and the evolving regulatory landscape, translating dense research and shifting rules into clear, usable guidance. Second, we sharpen patient-provider communication, giving clinicians practical language to discuss benefits, risks, and expectations without overpromising. Along the way, our panelists connect these skills to current cannabis market trends, cannabis business compliance expectations, and the wider cannabis industry opportunities opening for medically informed operators. Attendees will leave ready to lead more confident, evidence-based conversations that protect patients and strengthen the credibility of the entire field. Show MoreClick the title to see all detailsShow More

Panel DiscussionSession TypePharmaceutical & Clinical ResearchSession Track

More InformationExpand it to see more information related session.

Tags:Pharmaceutical & Clinical Research Insights

Allow Registration:No

Capacity Unlimited:No

Thu Dec 03•10:00 AM – 10:40 AM•Breakout Session Room 4 - N115

Google Calendar Apple Calendar Outlook Download .ICS file

Precision Medicine and AI: Engineering the Next Era of Cannabis and Psychedelics Therapeutics

Cannabis and psychedelic therapeutics sit at a scientific inflection p…Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocybin and MDMA across pain, treatment-resistant depression, PTSD, and neurological conditions. Yet the …Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocybin and MDMA across pain, treatment-resistant depression, PTSD, and neurological conditions. Yet the field still struggles with a core problem: variability. Patient responses differ widely based on genetics, metabolism, the endocannabinoid system, and complex entourage effects, making standardized do…Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocybin and MDMA across pain, treatment-resistant depression, PTSD, and neurological conditions. Yet the field still struggles with a core problem: variability. Patient responses differ widely based on genetics, metabolism, the endocannabinoid system, and complex entourage effects, making standardized dosing and reproducible outcomes difficult to achieve. Precision medicine and artificial intelligence offer a path forward. Machine learning models can analyze pharmacogenomic data, real-world evidence, and multi-omic datasets to predict individual responses, refine dosing protocols, and stratify patients for trials. AI-driven phenotyping and biomarker discovery accelerate the move from anecdotal use toward defensible, evidence-based therapeutics. This session unpacks the clinical and technological synergy reshaping the space. The panelists will examine algorithmic dosing models, predictive analytics in trial design, and the data infrastructure required to scale responsibly under evolving cannabis business compliance standards. Throughout, they’ll connect the science to current cannabis market trends and the commercial signals driving investment. Show MoreClick the title to see all detailsShow More